Aurinia Pharmaceuticals Inc (AUPH) concluded trading on Thursday at a closing price of $8.34, with 4.24 million shares of worth about $35.39 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 61.32% during that period and on November 07, 2024 the price saw a gain of about 10.90%. Currently the company’s common shares owned by public are about 143.83M shares, out of which, 128.68M shares are available for trading.
Stock saw a price change of 15.67% in past 5 days and over the past one month there was a price change of 23.56%. Year-to-date (YTD), AUPH shares are showing a performance of -7.23% which increased to 0.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.71 but also hit the highest price of $10.05 during that period. The average intraday trading volume for Aurinia Pharmaceuticals Inc shares is 1.17 million. The stock is currently trading 14.94% above its 20-day simple moving average (SMA20), while that difference is up 17.51% for SMA50 and it goes to 37.66% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) currently have 143.83M outstanding shares and institutions hold larger chunk of about 40.31% of that.
The stock has a current market capitalization of $1.19B and its 3Y-monthly beta is at 1.37. It has posted earnings per share of -$0.16 in the same period. It has Quick Ratio of 5.11 while making debt-to-equity ratio of 0.23. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AUPH, volatility over the week remained 5.11% while standing at 3.45% over the month.
Stock’s fiscal year EPS is expected to rise by 108.02% while it is estimated to increase by 1134.62% in next year.
Coverage by Cantor Fitzgerald stated Aurinia Pharmaceuticals Inc (AUPH) stock as an Overweight in their note to investors on May 05, 2022, suggesting a price target of $25 for the stock. On December 10, 2021, Oppenheimer Upgrade their recommendations, while on October 28, 2021, Oppenheimer Downgrade their ratings for the stock with a price target of $32. Stock get a Buy rating from H.C. Wainwright on January 25, 2021.
